The Use of Tacrolimus in 932 Renal Transplant Recipients

王意如,王学锋,刘世坤,张杰
DOI: https://doi.org/10.3969/j.issn.1001-0408.2002.04.017
2002-01-01
Abstract:OBJECTIVE:To objectively evaluate the immunosuppressive effect and safety of tacrolimus(FK 506) in renal transplant recipients METHODS:932 recipients receiving FK 506,reported in literature,were retrospectively analyzed RESU_LTS:The incidence of acute rejection was low in 547 recipients who received FK 506 immediately after transplantation Most of the recipients who received CsA and FK 506 successively showed alleviation of rejection and improvement of liver function The ARDs of FK 506 were rise of blood sugar(18 10%) and toxicity to nervous system(12 25%) CONCLUSION:FK 506 is a po_wer immunosuppressant and can be used to treat CsA-resistant rejection
What problem does this paper attempt to address?